548 related articles for article (PubMed ID: 29193006)
21. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.
Chihara D; Westin JR; Miranda RN; Cheah CY; Oki Y; Turturro F; Romaguera JE; Neelapu SS; Nastoupil LJ; Fayad LE; Rodriguez MA; Fowler NH; Orlowski RZ; Wang M; Hagemeister FB; Medeiros LJ; Fanale MA
Br J Haematol; 2017 Nov; 179(3):503-506. PubMed ID: 27378601
[No Abstract] [Full Text] [Related]
22. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
[TBL] [Abstract][Full Text] [Related]
23. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
Hallek M; Fischer K; Fingerle-Rowson G; Fink AM; Busch R; Mayer J; Hensel M; Hopfinger G; Hess G; von Grünhagen U; Bergmann M; Catalano J; Zinzani PL; Caligaris-Cappio F; Seymour JF; Berrebi A; Jäger U; Cazin B; Trneny M; Westermann A; Wendtner CM; Eichhorst BF; Staib P; Bühler A; Winkler D; Zenz T; Böttcher S; Ritgen M; Mendila M; Kneba M; Döhner H; Stilgenbauer S; ;
Lancet; 2010 Oct; 376(9747):1164-74. PubMed ID: 20888994
[TBL] [Abstract][Full Text] [Related]
24. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma.
Xu J; Oki Y; Saksena A; Desai P; Lin P; Tang G; Yin CC; You MJ; Thakral B; Medeiros LJ; Li S
Hum Pathol; 2017 Feb; 60():160-166. PubMed ID: 27816715
[TBL] [Abstract][Full Text] [Related]
25. Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia - an updated meta-analysis.
Vidal L; Gurion R; Shargian L; Dreyling M; Gafter-Gvili A
Br J Haematol; 2019 Jul; 186(2):234-242. PubMed ID: 30980398
[TBL] [Abstract][Full Text] [Related]
26. Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia.
Šimkovič M; Vodárek P; Motyčková M; Écsiová D; Rozsívalová P; Móciková H; Štěpánková P; Sýkorová A; Hrochová K; Vrbacký F; Belada D; Žák P; Smolej L
Eur J Clin Invest; 2021 Apr; 51(4):e13421. PubMed ID: 33022756
[TBL] [Abstract][Full Text] [Related]
27. Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma.
Olszewski AJ; Shafqat H; Ali S
Leuk Lymphoma; 2015 Apr; 56(4):942-50. PubMed ID: 24956144
[TBL] [Abstract][Full Text] [Related]
28. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.
Langerbeins P; Busch R; Anheier N; Dürig J; Bergmann M; Goebeler ME; Hurtz HJ; Stauch MB; Stilgenbauer S; Döhner H; Fink AM; Cramer P; Fischer K; Wendtner CM; Hallek M; Eichhorst B
Am J Hematol; 2014 Dec; 89(12):E239-43. PubMed ID: 25196783
[TBL] [Abstract][Full Text] [Related]
29. Richter syndrome: an aggressive transformation.
Streu E
Oncol Nurs Forum; 2015 Mar; 42(2):200-3. PubMed ID: 25806888
[TBL] [Abstract][Full Text] [Related]
30. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
[TBL] [Abstract][Full Text] [Related]
31. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
[TBL] [Abstract][Full Text] [Related]
32. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712
[TBL] [Abstract][Full Text] [Related]
33. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.
Mian M; Augustin F; Kocher F; Gunsilius E; Willenbacher W; Zabernigg A; Zangerl G; Oexle H; Schreieck S; Schnallinger M; Fiegl M
Anticancer Res; 2014 May; 34(5):2559-64. PubMed ID: 24778077
[TBL] [Abstract][Full Text] [Related]
34. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
Strüßmann T; Fritsch K; Baumgarten A; Fietz T; Engelhardt M; Mertelsmann R; Ihorst G; Duyster J; Finke J; Marks R
Br J Haematol; 2017 Sep; 178(6):927-935. PubMed ID: 28643323
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.
Tobinai K; Ogura M; Itoh K; Kinoshita T; Hotta T; Watanabe T; Morishima Y; Igarashi T; Terauchi T; Ohashi Y;
Cancer Sci; 2010 Dec; 101(12):2579-85. PubMed ID: 20942866
[TBL] [Abstract][Full Text] [Related]
36. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
Bouclet F; Calleja A; Dilhuydy MS; Véronèse L; Pereira B; Amorim S; Cymbalista F; Herbaux C; de Guibert S; Roos-Weil D; Hivert B; Aurran T; Dupuis J; Blouet A; Tchernonog E; Laribi K; Dmytruck N; Morel P; Michallet AS; Dartigeas C; Tournilhac O; Nguyen-Khac F; Delmer A; Feugier P; Ysebaert L; Guièze R
Ann Hematol; 2021 Apr; 100(4):987-993. PubMed ID: 33495922
[TBL] [Abstract][Full Text] [Related]
37. Hodgkin lymphoma transformation of chronic lymphocytic leukemia-A real life data from the Polish Lymphoma Research Group.
Drozd-Sokołowska J; Zaucha JM; Żółtak T; Jamroziak K; Grzybowska-Izydorczyk O; Witkowska M; Waszczuk-Gajda A; Kaźmierczak M; Szczepaniak A; Subocz E; Knopińska-Posłuszny W; Hołojda J; Kopińska A; Hus I; Rybka J; Wołowiec D; Kwiatkowski J; Hałaburda K; Smolewski P; Giebel S; Wiktor-Jędrzejczak W
Hematol Oncol; 2019 Oct; 37(4):383-391. PubMed ID: 31026087
[TBL] [Abstract][Full Text] [Related]
38. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Greil R; Obrtlíková P; Smolej L; Kozák T; Steurer M; Andel J; Burgstaller S; Mikušková E; Gercheva L; Nösslinger T; Papajík T; Ladická M; Girschikofsky M; Hrubiško M; Jäger U; Fridrik M; Pecherstorfer M; Králiková E; Burcoveanu C; Spasov E; Petzer A; Mihaylov G; Raynov J; Oexle H; Zabernigg A; Flochová E; Palášthy S; Stehlíková O; Doubek M; Altenhofer P; Pleyer L; Melchardt T; Klingler A; Mayer J; Egle A
Lancet Haematol; 2016 Jul; 3(7):e317-29. PubMed ID: 27374465
[TBL] [Abstract][Full Text] [Related]
39. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
[TBL] [Abstract][Full Text] [Related]
40. Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
Mauro FR; Galieni P; Tedeschi A; Laurenti L; Del Poeta G; Reda G; Motta M; Gozzetti A; Murru R; Caputo MD; Campanelli M; Frustaci AM; Innocenti I; Raponi S; Guarini A; Morabito F; Foà R; Gentile M
Am J Hematol; 2017 Jun; 92(6):529-535. PubMed ID: 28295527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]